z-logo
open-access-imgOpen Access
Prophylactic physiotherapy after thoracotomy and lung resection: is there really no benefit?
Author(s) -
Paula Agostini,
Sally Singh,
Babu Naidu,
P. Rajesh
Publication year - 2010
Publication title -
european journal of cardio-thoracic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 133
eISSN - 1873-734X
pISSN - 1010-7940
DOI - 10.1016/j.ejcts.2010.07.034
Subject(s) - thoracotomy , medicine , resection , physical therapy , lung , surgery
We read with interest the recently published randomised control trial (RCT) studying the effect of prophylactic physiotherapy following thoracotomy and lung resection [1]. The incidence of postoperative pulmonary complication (PPC) in both limbs of this trial was much lower than that anticipated by the authors (4.8% in the treatment group (n = 2) and 2.9% in the control group (n = 1)), and much lower than that reported in the literature [2], or indeed than that 18.5% (n = 10) previously reported by Reeve et al. [3], using the same diagnostic criteria [4]. The explanation cited for this was the variability in the definition of PPC in the literature, possible advancements in analgesia, more emphasis on early postoperative mobility, and use of a standardised clinical pathway. Based on their current results, the authors suggest that prophylactic physiotherapy may be unnecessary. However, the article failed to achieve adequate statistical power and we would not agree with this conclusion. Unfortunately, the study was not designed to measure the effectiveness of physiotherapy given to the patients most likely to benefit (having developed PPC). We commend the authors for their efforts, as there is a general lack of high-quality research in this field. This is a challenging area of research as there is a general reluctance of surgeons to withhold interventions believed to be important and effective, such as early mobilisation and chest clearance manoeuvres. In order to establish the true benefit of physiotherapy, or similar elements of the standardised clinical care pathway, an adequately powered multicentre RCT would have to be conducted, however, this seems unlikely on ethical/equipoise grounds. Given the small trial size and low incidence of PPC, we would be concerned that this article is open to misinterpretation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom